Summarize the article with AI
Retatrutide vs VK2735: The Short Answer
So far, retatrutide has the larger and longer results: 25.0% weight loss with 12 mg over 80 weeks in its main Phase 3 trial (28.3% if taken as intended), against up to 14.7% for VK2735's weekly injection in a 13-week Phase 2 trial. Neither is approved, and the two have not been tested against each other.
VK2735, from Viking Therapeutics, acts on GLP-1 and GIP receptors, the same pair as tirzepatide; retatrutide acts on those two plus the glucagon receptor. They are at different stages. Retatrutide has reported several Phase 3 trials lasting up to 80 weeks. VK2735's longest efficacy trial of the weekly injection, the Phase 2 VENTURE trial, lasted 13 weeks, and a 33-week Phase 1 maintenance study has reported topline results; its 78-week Phase 3 trials are still running. Because of that gap, there is no fair way yet to say which produces more weight loss.
What VK2735's Trials Have Shown
Weekly injection (VENTURE, Phase 2). In a 13-week trial of 176 adults with obesity, or overweight with a weight-related condition, Viking reported that the highest dose reduced weight by 14.7% from baseline, or 13.1% more than placebo. Up to 88% of people on VK2735 lost at least 10% of their weight, compared with 4% on placebo. Viking said most side effects, including gastrointestinal ones, were mild or moderate, and 13% of people on VK2735 stopped treatment, compared with 14% on placebo.
Oral tablet (VENTURE-Oral, Phase 2). Viking reported weight loss of up to 12.2% from baseline after 13 weeks, with up to 80% of people on VK2735 losing at least 10%. In July 2026 it said it expected to begin Phase 3 trials of the tablet in the fourth quarter of 2026.
Maintenance study (Phase 1). In September 2026, Viking reported a study of about 180 adults with obesity who lost 16% to 19% of their weight over 21 weeks of weekly injections and were then switched to less frequent doses or placebo for 12 weeks. Every-other-week dosing maintained up to 97% of the weight lost and monthly dosing up to 90%, compared with 61% on placebo. These are topline company results, not a peer-reviewed publication.
What Retatrutide's Trials Have Shown
In TRIUMPH-1, published in the New England Journal of Medicine in September 2026, 2,339 adults with obesity and without diabetes received retatrutide or placebo for 80 weeks. With 12 mg, weight fell by 25.0% counting everyone randomized, compared with 3.9% on placebo, or 28.3% if everyone had stayed on treatment. Its developer has also reported TRIUMPH-2, TRIUMPH-3, TRIUMPH-4 and TRANSCEND-T2D-1, and plans to submit retatrutide to the US Food and Drug Administration in the first quarter of 2027.
The closest retatrutide data to VK2735's 13-week results are early time points in retatrutide's 48-week Phase 2 trial, where the 12 mg group had lost 17.5% at 24 weeks, if taken as intended. That is still a different trial, length and population. How retatrutide's weight loss built up over time is covered in the retatrutide weight loss timeline.
Why 13-Week and 80-Week Results Cannot Be Compared
Weight loss with these drugs builds over many months, so a 13-week result and an 80-week result measure different things. A short trial cannot show where weight loss levels off, how many people stop treatment over a longer period, or how side effects change. The trials also differed in size, participants and how results were counted. VK2735's Phase 3 results will be the first that can be set alongside retatrutide's Phase 3 numbers, and even then the comparison will be across separate trials.
VK2735's Phase 3 Program
Viking's VANQUISH-1 trial enrolled about 4,500 adults with obesity, and VANQUISH-2 about 1,000 adults with type 2 diabetes and obesity or overweight. Both test weekly injections of 7.5 mg, 12.5 mg or 17.5 mg against placebo for 78 weeks, and Viking said in July 2026 that both were proceeding according to plan. In March 2026 it said it expected to complete the VANQUISH studies in 2027.
What Is Still Unknown
- How much weight people lose on VK2735 over 78 weeks.
- How the two drugs compare in the same kind of trial; we found no head-to-head study announced by either company.
- Whether the glucagon component gives retatrutide an advantage or a different side-effect profile compared with dual GLP-1/GIP drugs such as tirzepatide (see retatrutide vs tirzepatide vs semaglutide).
- Whether either drug will be approved.
Sources
- Viking Therapeutics. Topline results from the Phase 2 VENTURE trial of VK2735 in obesity. 2024.
- Viking Therapeutics. Results from the Phase 2 VENTURE-Oral Dosing trial of VK2735. 2025.
- Viking Therapeutics. Second quarter 2026 financial results and corporate update. July 29, 2026.
- Viking Therapeutics. Topline results from the VK2735 maintenance dosing study. September 22, 2026.
- Viking Therapeutics. Viking Therapeutics Announces Completion of Enrollment in Phase 3 VANQUISH-2 Trial of VK2735. March 26, 2026.
- Jastreboff AM, Kaplan LM, Davies MJ, et al. Retatrutide, a Triple Hormone Receptor Agonist, for Treatment of Obesity. N Engl J Med. Published September 29, 2026. DOI: 10.1056/NEJMoa2604169. (TRIUMPH-1)
- Jastreboff AM, Kaplan LM, Frías JP, et al. Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial. N Engl J Med. 2023;389(6):514–526.
- Eli Lilly. Lilly's triple agonist, retatrutide, successful in two additional Phase 3 obesity trials, delivering significant improvements in weight and A1C. July 23, 2026.
Medical Disclaimer: This article compares published trial results for general information only and is not medical advice. Retatrutide and VK2735 are investigational and neither is approved by the FDA for any use. Neither is available by prescription, and products sold online under the retatrutide name are not sold or supplied by Lilly. Nothing here is a recommendation to use, seek out or avoid any medication.
Frequently asked questions
That cannot be said yet. They have not been compared in the same trial, and they are at different stages. VK2735's weekly injection reduced weight by up to 14.7% in a 13-week Phase 2 trial; retatrutide 12 mg reduced weight by 25.0% over 80 weeks in Phase 3, counting everyone randomized. Results from such different trial lengths cannot be compared directly.
VK2735, from Viking Therapeutics, acts on GLP-1 and GIP receptors, the same pair as tirzepatide. Retatrutide acts on GLP-1, GIP and glucagon receptors. VK2735 is also being developed as an oral tablet; retatrutide has been studied as a weekly injection.
It is being developed as one. In a 13-week Phase 2 trial, the oral form reduced weight by up to 12.2% from baseline, according to Viking, which said in July 2026 that it expected to start Phase 3 trials of the tablet in the fourth quarter of 2026. It is not approved.
Its weekly injection is in two 78-week Phase 3 trials: VANQUISH-1, with about 4,500 adults with obesity, and VANQUISH-2, with about 1,000 adults with type 2 diabetes and obesity or overweight. Enrollment in both is complete. Viking said in March 2026 that it expects to complete the VANQUISH studies in 2027 and has not given a date for results.



